VALN

5.1603.82%
RL

Ralf Leo Clemens

Chair of Scientific Advisory Board

Dr. Ralf Leo Clemens, M.D, Ph.D., is Member of Scientific Advisory Board & Director of Inventprise, Inc. Dr. Clemens served as Non-Executive Director of Clover Biopharmaceuticals, Ltd. since June 17, 2022 until June 20, 2025. He serves as Member of Scientific Advisory Board at ILiAD Biotechnologies, LLC since 2024. He serves as Member of Scientific Advisory Board at Minervax ApS since October 2021. He serves as a Member of Scientific Advisory Board at Icosavax, Inc. He had been a Supervisory Director of Curevac N. V. since August 2015 until December 2023. Dr. Clemens is Principal and Founder of Grid Europe Ltd. Consulting (Global Research in Infectious Diseases) since 2015. He serves as Chair of Scientific Advisory Board at Valneva SE since July 2019 and was its Member of Supervisory Board from July 2016 to 2019. Dr. Clemens served as a Senior Vice President and Head of Development for Global Vaccine Business Unit at Takeda Pharmaceuticals International, Inc. from January 2012 to December 01, 2014. Dr. Clemens has been working in vaccine industry since 1988 in various senior scientific and business positions such as Head of GSK Biologicals’ vaccine development and Latin American business strategy from 1992 until 2006 and thereafter leading the global vaccine development at Novartis. In these years, he developed and brought to licensure more than 25 different vaccines globally. Dr. Clemens led the global vaccine development at Novartis from 2006 until 2012. Dr. Clemens served as the Head of Development - Novartis Vaccines of Novartis AG. Dr. Clemens has been working in the pharmaceutical industry since 1988 in various senior scientific and business positions. He served as Vice President Global Clinical R&D of GlaxoSmithKline Vaccines and of GSK’s Pharmaceuticals and Vaccines in Latin America. He was the Chairman of Scientific Advisory Board at CureVac N. V. until December 2023 and its Member of Scientific Advisory Board until 2024. He has been a Member of Supervisory Board at CureVac AG since March 2016. He serves as a Member of the Board of Trustees of the International Vaccine Institute IVI in Seoul, Korea and as external scientific advisor to the Bill & Melinda Gates Foundation. He served as a Member of Scientific Advisory Board - Prophylactic Vaccines at CureVac GmbH since July 2015. Dr. Clemens is the author of more than 150 publications and 250 presentations in the fields of vaccines, immunization and tropical medicine. He serves as external scientific advisor to the Institute of Infection and Global Health, University of Liverpool and to Aeras. He graduated in medicine with MD at the University of Mainz, Germany and holds an executive business degree from the Wharton Business School, Philadelphia, US.

Positions